Is choline kinase alpha a drug target for obesity?
Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions. Here we present our working model for how ChoKα could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoKα as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.
Authors
- Juan Carlos Lacal (ORCID: https://orcid.org/0000-0002-1908-2777)
- Salam A. Ibrahim (ORCID: https://orcid.org/0000-0001-5395-9993)
- Tahl Zimmerman (ORCID: https://orcid.org/0000-0001-5939-6394)
Institutions
- High Point University (US)
- Consejo Superior de Investigaciones Científicas (ES)
- North Carolina Agricultural and Technical State University (US)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.3389/fendo.2024.1492753
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wake Forest University
- Agencia Estatal de Investigación